Skip to main content

Table 3 Univariate analysis of primary and secondary outcomes

From: Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction

 

Primary outcome

Secondary outcome

HR

95% CI

P value

HR

95% CI

P value

Age (years)

0.993

0.973–1.013

0.487

0.991

0.970–1.011

0.373

Male gender

1.350

0.693–2.631

0.378

0.726

0.388–1.361

0.318

Mean arterial pressure (mmHg)

0.971

0.945–0.997

0.028

0.959

0.931–0.986

0.004

Hypertension

1.257

0.663–2.384

0.483

0.896

0.449–1.789

0.756

Diabetes mellitus

1.417

0.712–2.818

0.321

1.387

0.679–2.833

0.369

Dyslipidemia

1.521

0.469–4.936

0.485

0.945

0.228–3.917

0.938

Current smoker

0.978

0.474–2.017

0.951

0.853

0.403–1.807

0.678

Chronic kidney diseasea

1.660

0.813–3.389

0.164

1.709

0.837–3.492

0.141

Previous CVA

3.501

1.079–11.362

0.037

2.265

0.545–9.418

0.261

Body mass index, kg/m2

0.960

0.888–1.037

0.298

0.936

0.858–1.021

0.134

ECG at baseline

      

 Heart rate (bpm)

1.000

0.984–1.015

0.972

1.013

0.997–1.029

0.109

 Left bundle-branch block

1.122

0.519–2.426

0.770

1.580

0.774–3.224

0.209

 QRS duration (ms)

1.005

0.995–1.015

0.353

1.003

0.993–1.013

0.598

Laboratory data

      

 Serum creatinine (mg/dl)

2.249

0.784–6.455

0.132

0.950

0.271–3.334

0.950

 Na (mmol/l)

0.810

0.751–0.875

< 0.001

0.860

0.794–0.931

< 0.001

 ln(NT-proBNP) (pg/ml)

1.376

1.083–1.748

0.009

1.519

1.190–1.939

0.001

Cardiac medications

      

 Beta-blockers

1.148

0.564–2.334

0.704

0.767

0.396–1.486

0.432

 ACE-inhibitors/ARB

1.492

0.531–4.192

0.447

2.171

0.669–7.050

0.197

 Spironolactone

1.100

0.588–2.056

0.766

1.380

0.724–2.632

0.328

 Diuretics

0.921

0.463–1.832

0.814

1.732

0.767–3.914

0.187

 Digoxin

1.658

0.847–3.242

0.140

1.662

0.847–3.258

0.140

LV EF (%)

1.006

0.969–1.044

0.759

0.970

0.933–1.009

0.132

LV EDV (ml)

1.003

1.000–1.006

0.093

1.003

1.000–1.006

0.090

LV ESV (ml)

1.003

0.999–1.006

0.108

1.004

1.000–1.007

0.041

Cardiac output (L/min)

1.092

0.908–1.314

0.349

0.961

0.784–1.177

0.699

Cardiac index (L/min/m2)

1.228

0.868–1.738

0.245

1.024

0.708–1.481

0.901

RV EF (%)

0.984

0.964–1.005

0.124

0.976

0.955–0.998

0.033

RV EDV (ml)

1.005

1.000–1.009

0.041

1.004

0.999–1.009

0.080

RV ESV (ml)

1.005

1.000–1.009

0.049

1.005

1.000–1.010

0.045

RV stroke volume (ml)

1.007

0.991–1.024

0.376

0.995

0.977–1.012

0.556

RV cardiac output (L/min)

1.122

0.894–1.407

0.320

0.962

0.759–1.220

0.751

Presence of LGE

2.277

1.221–4.246

0.010

2.023

1.066–3.839

0.031

Myocardial mass (g)

0.997

0.990–1.005

0.510

0.987

0.978–0.997

0.008

Quantitative LGE mass (g)

1.014

0.998–1.031

0.086

1.009

0.990–1.028

0.370

LGE mass/LV myocardial mass (%)

1.024

0.998–1.051

0.068

1.018

0.989–1.047

0.232

Global radial strain (%)

0.974

0.921–1.030

0.363

0.955

0.901–1.013

0.129

Global circumferential strain (%)

1.030

0.934–1.136

0.554

1.062

0.963–1.172

0.229

Global longitudinal strain (%)

1.048

0.945–1.163

0.375

1.066

0.955–1.191

0.254

  1. aChronic kidney disease was defined as eGFR < 60 ml/min/1.73m2, calculated using the 4-component MDRD study equation
  2. Abbreviations: ACE angiotensin-converting-enzyme, ARB angiotensin II receptor blockers, BNP B-type natriuretic peptide, CI confidence interval, CVA cerebrovascular accident, ECG, electrocardiography, EDV end-diastolic volume, EF, ejection fraction, ESV, end-systolic volume, HR, hazard ratio, LGE late gadolinium enhancement, LV, left ventricle, RV, right ventricle
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us